news
Discovery unveils genetic risk factor shared by Alzheimer’s and COVID-19
Scientists have identified the OAS1 gene as a risk factor for both Alzheimer's disease and COVID-19, suggesting potential drug targets.
List view / Grid view
Drug Development
article
Are computer simulations the future of rapid COVID-19 drug development?
Researchers have visualised SARS-CoV-2 protein dynamics using in silico methods. In this article, Navodya Roemer explains how a team from the University of Warwick developed a computational strategy that could assist scientists in the production of new treatments and drugs for COVID-19.
news
Pre-clinical trials to test if psychedelic drugs reduce alcohol consumption
Landmark pre-clinical studies to investigate whether psychedelic derivatives can reduce alcohol consumption have been initiated.
news
Psilera to collaborate with NIDA on pre-clinical psychedelic studies
Psilera will participate in two studies with the National Institute on Drug Abuse to combat addiction using a novel DMT formulation.
article
AI & Informatics: Drug discovery and development – industry survey infographic
View Drug Target Review's new infographic on the use of AI and informatics within early therapeutic development here.
news
Psilocybin spurs growth of neural connections lost in depression in vivo
Research from Yale University has shown that psilocybin, given to mice, triggered an increase in connections between neurons.
article
Targeting SARS-CoV-2 replication with inhibitors of lipid metabolism
One approach towards efficient drug targeting efforts for COVID-19 is to repurpose medicines developed for other diseases. Here, Professor Christopher Basler outlines a recent study, published in Cell Reports, where scientists from the Institute for Biomedical Sciences at Georgia State University, US, in collaboration with industry partners, developed assays to…
news
New measures to minimise animal testing to be implemented in Europe
The European Medicines Agency is promoting three principles – replace, reduce and refine – to reduce animal testing in medicine development.
article
High-throughput 3D cell migration assays in organ-on-a-chip technologies
Organ-on-a-chip models can provide an alternative to cell cultures, animal models and traditional assays. In this article, Dr Désirée Goubert, Thomas Olivier, Luuk de Haan and Dr Lenie van den Broek explore the advantages of organ-on-a-chip technologies and how they can enable the in vitro study of three-dimensional (3D) cell migration in…
article
Targeting disease pathways to treat ulcerative colitis – beyond corticosteroid use
Dr Chetan Karyekar, Compound Development Team Leader at The Janssen Pharmaceutical Companies of Johnson & Johnson (J&J), explains how targeting underlying immune pathways can open the door to effectively treating more inflammatory bowel disease (IBD) patients by reducing or eliminating the chronic use of corticosteroids.
whitepaper
Product hub: High-throughput screening of cyclic peptide libraries for developing drugs to challenging targets
Professor Christian Heinis explains how peptides could offer the next generation of therapeutics and what is required to screen libraries of cyclic peptides.
news
Promising pre-clinical data announced for Parkinson’s drug
Stealth BioTherapeutics reported positive data from a pre-clinical study evaluating SBT-272 in a murine model of Parkinson's disease.
news
Sanofi acquires Translate Bio for mRNA therapeutic development
Sanofi has completed the acquisition of mRNA therapeutics company Translate Bio for a total of approximately $3.2 billion.
article
Why there is a blockage in the biosample system
Dr Robert Hewitt explores why a shift is required in the way that biosamples are sourced by the drug discovery industry, including smaller biotech companies.
article
An IgM antibody platform to tackle SARS-CoV-2 and its variants
Despite the rapid deployment of vaccines among global populations, therapeutics such as antibodies are still required. Here, Dr Steve Carroll, Vice President of Pre-clinical Sciences at IGM Biosciences, explains how a potential Immunoglobulin M (IgM) antibody treatment has been developed that shows promise for combatting SARS-CoV-2 and variants of concern in pre‑clinical…
